Estrogen replacement therapy in patients with endometrial cancer: a survey of prescription intention of Belgian gynecologists.
Explore the source record for details and available documents.
Attitude of Health Personnel↗
Biomedical subjects
S Rozenberg
Publications and source records attributed to S Rozenberg.
Managing the climacteric.
HRT taken for a sufficient duration may reduce the occurrence of osteoporosis and of cardiovascular disease by up to 50% and possibly also reduce incidence and lessen severity of Alzheimer's disease. Nevertheless, it is often only prescribed when women request it to relieve climacteric symptoms. Furthermore, many physicians prescribe it for only limited periods of time and few are willing to prescribe it to women in their sixties. As with any long-term prevention strategy, the uptake of HRT is much lower than the prescription rate, since the medication is often abandoned due to side effects or due to lack of motivation. But HRT is often abandoned also due to fear of cancer. While physicians may be aware of some beneficial effects of HRT, they often have no time to inform their patients of them. Alternatively, some of the beneficial effects such as cardioprotection or a reduced incidence of Alzheimer's may be less known. Likewise, HRT-related side effects or risks such as breast cancer or thromboembolic diseases should be discussed prior to HRT prescription. Women need to be informed about these potential risks, and this should be done by their physician. Surveys have shown that many women feel that they receive insufficient information from their physician. The quality of the relationship between physician and patient probably has a large influence on HRT acceptance, but very few studies have been conducted to assess specifically factors influencing the prescription and the continuation rate of HRT. Simple strategies may be among the most effective ones; these include listening to patients' fears, complaints and questions, and taking the time to answer them. The role of a practice nurse in such a setting may be also very important.
Attitude to Health↗
Are children also fated to develop back pain?
Explore the source record for details and available documents.
Adolescent↗
Osteoporosis management.
About 40% of women who reach the age of 50 are expected to suffer from osteoporosis during their remaining life. The morbidity associated with hip, spinal and wrist fractures, resulting from osteoporosis, and the mortality resulting from hip fractures justify the development of prevention strategies. Optimal management of osteoporosis consists of maximizing peak bone mass in early adulthood and preventing the rapid bone loss that occurs soon after the menopause. Peak bone mass will be reached in most women if adequate nutrition is taken and exercise is encouraged, while major risk factors are avoided. At the menopause, prescription of hormone replacement therapy (HRT) constitutes the primary prevention strategy. There are, however, questions that remain unanswered or debated. What is the optimal dose of HRT, when should it be started, and for how long should it be maintained? In women who do not, or may not, take HRT, and who have osteoporosis, alternative therapeutic options include diphosphonates (e.g., alendronate) and Selective Estrogen Receptor Modulators (such as raloxifene). Other treatments to restore bone strength in women with established disease may also reduce the risk of fractures. Some of them, such as calcitonin, may not be cost effective. Others have produced conflicting data (fluoride) and others are still under evaluation (PTH or strontium). In sunlight-deprived, vitamin D-deficient elderly nursing home residents, dietary supplementation of calcium and vitamin D has been shown to prevent bone loss and fractures. Strategies to avoid falls should also be encouraged for these patients.
Aged↗
The menopause in Europe.
Most women in developed countries will live a third of their lives after the menopause. Vasomotor symptoms (hot flushes, night sweats, irritability, sleep disturbances, mood swings), and urogenital complications (atrophic vaginal irritation and dryness, dyspareunia) occur frequently during this period of life, but their severity and duration may vary widely between individuals. The menopause also induces accelerated bone loss and is the principal risk factor for osteoporosis. Hormone replacement therapy (HRT; estrogen or estrogen plus progestogen) alleviates these symptoms and can be administered orally, transdermally, topically, intranasally, or as subcutaneous implants. HRT is also effective for prevention and treatment of postmenosausal osteoporosis throughout the time that it is used. It is not surprising that HRT use has increased substantially during the past decade. Nevertheless, there are still considerable variations in use between different countries within the European community. This presentation will analyze: the frequency of menopausal symptoms among women in different European countries and the factors that influence them; the frequency of other postmenopausal women's health issues in Europe; the use of HRT in Europe as well as the type of HRT and its evolution during the last decade; and possible reasons explaining heterogeneity between countries.
Aged↗
Guidelines for clinical studies assessing the efficacy of drugs for the management of acute low back pain.
In this paper we propose guidelines for clinical trials aimed at assessing the efficacy of drugs for acute non-specific low back pain (LBP) with or without radicular pain, preliminary to their approval and registration. To this end, consensus statements were obtained from a group of experts in the fields of rheumatology, clinical medicine, public health and epidemiology. EBM resources were systematically used as references. Four diagnostic categories were defined: type 1--LBP with no radiation; type 2--LBP radiating no further than the knee; type 3--LBP radiating beyond the knee, but with no neurologic signs; and type 4--LBP radiating to a specific and entire leg dermatome, with or without neurologic signs. Studies should be designed on the basis of the claimed indications for the drug, but must be double-blinded whatever the indication. The duration of the study may be shorter for LBP type 1 or 2 (one week) than for LBP types 3 and 4 (up to one month), depending on the aim of the study and the indications for the drug. The comparator may be inactive (placebo) or active (for a superiority trial, e.g., versus paracetamol). Specific inclusion and exclusion criteria have been defined here for each category. An appropriate wash-out period for any drugs that could affect the pain status should be planned. Paracetamol may be allowed as rescue medication. The primary endpoint should be based on a validated pain assessment tool that may be either generic (type 1 or 2) or oriented (back and knee for types 3 and 4). Secondary endpoints could include the assessment of functional performance; the duration of any period of bed-rest; work limitation; a global assessment comprising pain at rest, standing and walking; the time elapsed before epidural injection, the prescription of other therapeutic agents, or surgery; and the use of rescue medication. Adverse events (AE) should be monitored systematically using a methodology that reflects the mode of action of the tested drug. With the application of these guidelines, LBP could serve as an appropriate disease for testing analgesic drugs. Rigorous evaluation may also help to improve the management of acute LBP.
Acute Disease↗
Estrogen therapy in older patients with recurrent urinary tract infections: a review.
Although urogenital complaints, such as recurrent lower urinary tract infections (UTI), and dysuria, are commonly encountered in elderly women, few women have participated in randomized studies of estrogen therapy for this condition. This is a paradox in view of the often cited beneficial effect of estrogen in reducing the incidence of UTI. Present evidence documents that in postmenopausal women, hormone replacement therapy using topical estrogen normalizes the vaginal flora and greatly reduces the risk of vaginal atrophy. Similarly, vaginal estrogen administration seems to be effective for preventing recurrent urinary tract infections (UTI).
Administration, Intravaginal↗
[Compliance with hormone replacement therapy].
Hormone Replacement Therapy (HRT) after menopause reduces climacteric symptoms and increases the quality of life. If correct dosage is used, bone loss can be prevented and fracture frequency reduced. Epidemiological studies also suggest a decreased cardio-vascular mortality among HRT users. A high proportion of post-menopausal women should therefore be treated using long-term therapy, but currently only a small proportion of women use HRT in Belgium, (around 14%). Further their compliance is particularly low. Fear of cancer and drug-related side effects, such as unaccepted bleeding are often mentioned causes of low compliance. Education of both physicians and patients, regarding HRT seems to be a crucial issue. The physician's attitude towards HRT is often reported as negative. Osteoporosis prevention and related bone mass measurements may have a favorable effect on compliance, but this is not well established. Establishing a confidential relationship with patients and the involvement of nursing counseling are strategies which may improve compliance. The use of easy-to-take medications supported by calendar blisters or reminders, may facilitate chronic use of medication. Future research needs to investigate the physician's and the patient's decision-making process.
Aged↗
Overview of the clinical usefulness of bone mineral measurements in the prevention of postmenopausal osteoporosis.
Bone mass measurements might be useful in two ways in prevention of postmenopausal osteoporosis: the decision to start HRT, or other therapy, could be based on such measurements; and, possibly, compliance to treatment would be enhanced. Bone density measurement appears to have sufficient predictive value for osteoporotic fracture, especially when density is measured by dual-energy X-ray absorptiometry. However, choice of skeletal site for the measurement cannot be made with certainty, although a vertebral site may be best early in menopause; and in women with osteophytes or scoliosis, and with older women, the femur or wrist may be preferred. With respect to enhancement of patients' compliance to HRT, as well as clinicians' willingness to prescribe treatment, it has not yet been clearly shown that bone mass measurements have a significant effect. This topic involves economic efficiency and should be evaluated by considerations of economics weighted against medical efficacy.
Adult↗
Osteoporosis prevention with sex hormone replacement therapy.
It was suggested as long ago as 1941 that there might be a connection between the menopause and osteoporosis. Since then, abundant data have confirmed that hypothesis as well as showing that such osteoporosis may be prevented by estrogen supplementation (ERT--estrogen replacement therapy). In estrogen deficiency, increased bone resorption takes place in the process of bone remodeling, leading to bone loss. The bone loss occurs universally but to the greatest extent at sites rich in trabecular bone. There are uncertainties concerning extent of bone loss at various sites at different ages, effect of ERT at varying sites and different ages, degree of fracture prevention, and relationship between duration of therapy and fracture risk. That optimal fracture risk is not being attained now on a population basis is due to apparently low acceptance of ERT by patients and lack of strenuous effort in that direction by physicians.
Age Factors↗
Bone mineral content of women with uterine fibromyomas.
OBJECTIVE: To determine if the bone mineral content (BMC) of women suffering from fibroids is different from that of the reference population. DESIGN: Cross-sectional retrospective study. PARTICIPANTS: Fifty-nine women suffering from fibroids, compared to the reference population. OUTCOME MEASURES: BMC was measured at the vertebral L2-L4 site (BMC-1) and at the midradius site (BMC-r). RESULTS: The patients with fibroids exhibited no significant difference in BMC-r). RESULTS: The patients with fibroids exhibited no significant difference in BMC-r, but had a significantly higher (P < or = .001) BMC-1 than the reference population. CONCLUSION: Since BMC-1 is mainly constituted by trabecular bone and BMC-r by cortical bone, and since trabecular bone is more sensitive to estrogens than cortical bone, it is suggested that a hyper-estrogenic state co-existing with fibroids may induce a slight protective factor against osteoporosis of the vertebral skeleton.
Adult↗
Principal cancers among women: breast, lung and colorectal.
The major variations in the pattern and level of cancer throughout the world reflect for the most part differences in the environment. It is generally agreed that carcinogenesis may arise as a result of chemical, physical, biologic, and genetic insults to cells. In addition, specific external factors may initiate and/or support malignant transformation, such as smoking, occupational and environmental chemicals, radiation, dietary factors, and specific viruses. Furthermore, endogenous compounds, such as steroid sex hormones, may be promoters for carcinogenesis of hormone-dependent tissue. Although some cancers seem to be related to inherited traits, research generally does not support the notion of group or inherited differences in cancer statistics. The leading causes of cancer death in females in 1991 in the United states were lung cancer (52,068), breast cancer (43,583), and colorectal cancer (29,017). According to the American Cancer Society, this year 182,000 women will be diagnosed with breast cancer, 73,900 with lung cancer, and 66,000 with colorectal cancer. Even with our knowledge about the influence of life style and environmental causes of cancer, little progress has been made. In breast cancer, only 25 to 30% can be attributed to known risk factors. Lung cancer in females, on the other hand, once a rare disease, turns out to be the leading cause of cancer death among women in industrialized countries, mostly due to smoking.
Breast Neoplasms↗
The brittle bone: how to save women from osteoporosis.
For a woman, the risk of suffering an osteoporotic fracture during her lifetime is higher than the combined risk of breast, endometrial, and ovarian cancer. It is important to reduce the number of osteoporosis-related fractures. Therefore, it is necessary to emphasize various interventions and attitudes which will decrease both the risk of falling and that of breaking bones. Strategies should be followed to reach adulthood with an optimal bone mass through improved diet and exercise during childhood. Programs that identify women with the lowest bone mass at the time of menopause may be useful, since prophylactic measures against osteoporosis such as hormone replacement therapy (HRT) can be offered to them. Identification of women at risk can be achieved through bone densitometry; a decrease of each standard deviation of bone mineral mass below mean values predicts a doubling of the fracture risk. Some data suggest that physicians are more willing to prescribe HRT specifically to women with the lowest bone mass, and that the latter are more likely to stay on therapy for longer periods of time. The decision to use HRT should be taken by the patient after proper information of all benefits (diminished climacteric symptoms, decrease of cardiovascular risk) and potential risks (possible enhanced breast cancer risk, appearance of side effect). In women who do not want to take HRT, or for whom contraindications exist, alternative medications, such as calcium, vitamin D and biphosphonates can be considered, depending on fracture risk. For older and institutionalized women, programs should be developed to decrease the risk of falling. Likewise, it may be possible to reduce the consequences of a fall, for instance by promoting the development of energy-absorbing hip pads, which reduce fracture risk.
Bone Density↗
Effect of estrogen replacement therapy with or without concomitant nonsteroidal anti-inflammatory drugs on pulsatility and resistance index of uterine arteries in healthy postmenopausal women.
OBJECTIVE: This study assesses the existence of a prostaglandin-mediated effect of estrogen on uterine arteries. METHODS: The pulsatility index (PI) and the resistance index (RI) of 10 postmenopausal women aged 50 to 65 who had not been on estrogen replacement therapy (ERT) for the 6 weeks preceding the study were measured at baseline level (T1), after randomization for either placebo or nonsteroidal anti-inflammatory drug (NSAID) (600 mg of Sulindac for one day) (T2), after 1 week of washout and cross-over (T3). They were then supplemented with ERT (transdermal system 50 micrograms/d, twice a week, Systen) for a period of 3 months. PI and RI of uterine arteries were assessed again while using ERT (T4), after either placebo or NSAID for one day (T5) and after 1 week of placebo-NSAID cross-over (T6). Assays of total cholesterol as well as the HDL, HDL2, LDL, triglycerides, endothelin-1, lipoprotein (a), estradiol and FSH were also obtained at baseline before receiving ERT and after 3 months of ERT. RESULTS: A small but significant increase of the PI was observed after NSAID intake as compared to the baseline measurement (P < .05), but no difference was observed for the RI. After estrogen treatment for 12 weeks, no difference was found between baseline measurements and the placebo intake or the NSAID intake. CONCLUSION: These results do not confirm a modulation by prostaglandin of the estrogen cardioprotective effect, although it is possible that the study lacks power.
Aged↗
Inhospital management of common lumbosciatic syndrome. An opinion survey among French rheumatologists.
To determine which treatments are most commonly offered to patients younger than 70 years of age admitted for uncomplicated lumbosciatica suggestive of disk herniation, we sent a 43-item questionnaire to 106 rheumatology departments in France. The questionnaire collected information on hospital stay duration, modalities of rest, drug treatments, local glucocorticoid injections, physical treatments, sick leave duration and advice given to the patients. The response rate was 77% (84 questionnaires). Substantial variations were found across departments. Hospital stay duration ranged from five to 20 days and nonsteroidal antiinflammatory drug treatment duration from five to 30 days. Local glucocorticoid therapy was given as one to four injections at intervals of two to seven days. Spinal traction was used in 38% and a corset in 50% of study centers. Neither was there any consensus regarding immediate or delayed physiotherapy. Most respondents recommended bedrest for no longer than 15 days, a nonsteroidal antiinflammatory drug, a level I or II analgesic, local glucocorticoid injections and, in the event of persistent pain at the end of the hospital stay, a lumbar corset.
Aged↗